Long-term safety of abatacept in patients with rheumatoid arthritis

Fabiola Atzeni, Piercarlo Sarzi-Puttini, Alessandra Mutti, Serena Bugatti, Lorenzo Cavagna, Roberto Caporali

Research output: Contribution to journalArticle

Abstract

Abatacept is a selective T cell co-stimulation modulator that was first approved by the Italian Medicines Agency and reimbursed by the Italian National Health Service when used to treat active rheumatoid arthritis "not sufficiently responsive to other disease-modifying anti-rheumatic drugs (DMARDs) including at least one TNF inhibitor", and is now also approved as a first line biological agent. The aim of this review is to summarise the safety data collected in clinical trials and observational studies.

Original languageEnglish
Pages (from-to)1115-1117
Number of pages3
JournalAutoimmunity Reviews
Volume12
Issue number12
DOIs
Publication statusPublished - Oct 2013

    Fingerprint

Keywords

  • Abatacept
  • Rheumatoid arthritis
  • Safety

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this